News

Filter

1 to 9 of 12 results

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Generic erosion will constrain hospital-acquired infections drug market growth through 2019

14-12-2010

The advent of generic versions of nine branded agents will significantly constrain growth in the hospital-acquired…

Antibiotics and Infectious diseasesAstellas PharmaAstraZenecaForest LaboratoriesGenericsMarkets & MarketingPharmaceuticalTeflaroTheravancetorezolidTruisVibativ

Crisis in CEE pharma innovative market

22-12-2008

Innovative pharmaceutical companies face a crisis associated with the loss of patent rights pertaining…

Astellas PharmaAstraZenecaAventis PharmaGlaxoSmithKlineGSKNovartisPfizerSanofi-Aventis

Japanese drug industry groups call for improved discovery environment

11-08-2008

Major Japanese drug industry organizations, including the Federation of Pharmaceutical Manufacturer Associations…

Astellas PharmaAstraZenecaJohnson & JohnsonSankyo

1 to 9 of 12 results

COMPANY SPOTLIGHT

Menarini

Back to top